Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes . Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this in using insurance claims data. They found that semaglutide and tirzepatide – marketed as Ozempic and Mounjaro – reduced the risk of serious cardiovascular events by up to 18 percent.

The study, published in Nature Medicine , analyzed a large dataset from US health insurers. "Those data are collected in routine clinical care and can be used for research. They allow us to answer a broad range of relevant questions efficiently. Importantly, we are studying patients who reflect everyday clinical practice – unlike the highly selected participants typically enrolled i

See Full Page